SilcsBio LLC
SilcsBio is a technology company specializing in structure-based drug design, molecular visualization, and data mining. Their proprietary SILCS platform technology enables rapid identification of binding hotspots on target proteins, facilitating the development of effective drug candidates and biologics. The company offers software and services that span from protein surface mapping to lead optimization, aiming to accelerate drug discovery and reduce development costs. SilcsBio collaborates with academic and industry partners to advance computational drug design applications.
Industries
Nr. of Employees
small (1-50)
SilcsBio LLC
Baltimore, Maryland, United States, North America
Products
Protein free-energy mapping platform
A computational platform that generates 3D free-energy maps of protein surfaces to identify binding hotspots, guide docking, and inform ligand design.
Computational biologics formulation toolkit
Simulation workflows that predict excipient binding and excipient–protein interactions to inform formulation choices for protein therapeutics.
Force field parameterization web tool
Web-accessible tools for force field parameter assignment to support MD simulations and accurate ligand modeling.
High-throughput docking and near-FEP affinity prediction suite
Integrated docking, ML scoring, and single-step FEP workflows to perform fast ligand ranking with accuracy comparable to more computationally expensive FEP approaches.
Protein free-energy mapping platform
A computational platform that generates 3D free-energy maps of protein surfaces to identify binding hotspots, guide docking, and inform ligand design.
Computational biologics formulation toolkit
Simulation workflows that predict excipient binding and excipient–protein interactions to inform formulation choices for protein therapeutics.
Force field parameterization web tool
Web-accessible tools for force field parameter assignment to support MD simulations and accurate ligand modeling.
High-throughput docking and near-FEP affinity prediction suite
Integrated docking, ML scoring, and single-step FEP workflows to perform fast ligand ranking with accuracy comparable to more computationally expensive FEP approaches.
Services
Consulting engagements to implement mapping, screening, and lead-optimization workflows; training for client teams; and project support for discovery programs.
Recorded webinars and presentations covering platform updates, methodology, and application case studies for practitioner education and adoption.
Collaborative project work that applies mapping, screening, ML, and lead-optimization workflows to client targets and discovery programs with integration of experimental confirmation.
Consulting engagements to implement mapping, screening, and lead-optimization workflows; training for client teams; and project support for discovery programs.
Recorded webinars and presentations covering platform updates, methodology, and application case studies for practitioner education and adoption.
Collaborative project work that applies mapping, screening, ML, and lead-optimization workflows to client targets and discovery programs with integration of experimental confirmation.
Expertise Areas
- Structure-based drug design
- Molecular dynamics and enhanced sampling
- High-throughput virtual screening
- Machine learning for ligand discovery and optimization
Key Technologies
- Grand Canonical Monte Carlo (GCMC)
- Molecular Dynamics (MD)
- Grid-based free-energy FragMaps
- Monte Carlo docking (MC docking)
News & Updates
Showcasing the latest advancements in SILCS v2025, focusing on improving accuracy, usability, and flexibility in computer-aided drug design.
SilcsBio was designated for inclusion in the NIH Innovation Zone at BIO Digital 2021, showcasing their healthcare technologies and hosting a presentation on their expertise in drug design.
A study on how electronic polarizability affects interactions between proteins and functional groups, published in 2020.
A case study demonstrating SILCS technology's ability to predict binding sites, refine ligand poses, and rank ligands for the KRAS G12D target.
SilcsBio announced the issuance of a US patent covering key elements of its drug design software, enhancing its intellectual property portfolio.
Showcasing the latest advancements in SILCS v2025, focusing on improving accuracy, usability, and flexibility in computer-aided drug design.
SilcsBio was designated for inclusion in the NIH Innovation Zone at BIO Digital 2021, showcasing their healthcare technologies and hosting a presentation on their expertise in drug design.
A study on how electronic polarizability affects interactions between proteins and functional groups, published in 2020.
A case study demonstrating SILCS technology's ability to predict binding sites, refine ligand poses, and rank ligands for the KRAS G12D target.
SilcsBio announced the issuance of a US patent covering key elements of its drug design software, enhancing its intellectual property portfolio.